All In Biotech

Drug Trial Radar · NCT07898800

Safety, Tolerability And Pharmacodynamics of DM-101PX in Birch Pollen Allergy

A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability And Pharmacodynamics of Subcutaneous Immunotherapy With DM-101PX in Subjects With Birch Pollen Allergy

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Oct 29, 2026

Primary completion

Mar 2027

Study completion May 2027

Sponsor

Lead sponsor
Desentum OyIndustry
Sponsor type
Industry
First posted
Oct 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Randomized, double-blind placebo-controlled phase I trial with the primary aim to investigate safety and tolerability of DM-101-PX compared to placebo in birch pollen allergic adults. As an secondary objectives, the trial will also assess the number of participants receiving the maximum intended DM-101PX dose and to assess the effect of treatment with DM-101PX compared with placebo on blood allergy biomarkers. Expanded access to the study treatment is not available.

Conditions

  • Birch Pollen Allergy

Interventions

  • DM-101PXBiological

    Subcutaneous injection of DM-101PX

  • PlaceboBiological

    Placebo to match subcutaneous injection of DM-101PX

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Emergent Adverse EventsTime frame: From the first dose to until 3 months from the last dose
  2. Adverse Events of Special InterestTime frame: From the first dose to until 3 months from the last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fraunhofer Institute for Toxicology and Experimental Medicine ITEM

    Hanover, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.